{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:07:58Z","timestamp":1794564478314,"version":"4.9.1"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002749","name":"BELSPO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002749","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["PDM\/17\/178"],"award-info":[{"award-number":["PDM\/17\/178"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.antiviral.2018.03.003","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:22:05Z","timestamp":1520468525000},"page":"85-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":341,"special_numbering":"C","title":["Favipiravir as a potential countermeasure against neglected and emerging RNA viruses"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8874-675X","authenticated-orcid":false,"given":"Leen","family":"Delang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Abdelnabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.03.003_bib1","article-title":"Antiviral treatment efficiently inhibits chikungunya virus infection in the joints of mice during the acute but not during the chronic phase of the infection","author":"Abdelnabi","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00487-17","article-title":"Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): key role of the F1 motif of the viral polymerase","volume":"91","author":"Abdelnabi","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.03.003_bib3","doi-asserted-by":"crossref","first-page":"e03679","DOI":"10.7554\/eLife.03679","article-title":"Favipiravir elicits antiviral mutagenesis during virus replication in vivo","volume":"3","author":"Arias","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.antiviral.2018.03.003_bib4","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705) - Sierra Leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.03.003_bib5","first-page":"2470","article-title":"An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy","volume":"70","author":"Bank","year":"2016","journal-title":"Evol. (N. Y)"},{"key":"10.1016\/j.antiviral.2018.03.003_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2017.10.109","article-title":"Re-evaluating the effect of Favipiravir treatment on rabies virus infection","author":"Banyard","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.03.003_bib7","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.03.003_bib8","doi-asserted-by":"crossref","DOI":"10.3851\/IMP3180","article-title":"In vitro susceptibility of geographically and temporally distinct zika viruses to favipiravir and ribavirin","author":"Baz","year":"2017","journal-title":"Antivir. Ther."},{"issue":"17","key":"10.1016\/j.antiviral.2018.03.003_bib9","first-page":"S0166","article-title":"Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus","author":"Bixler","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib10","article-title":"Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus","author":"Bixler","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib11","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/nar\/gkg277","article-title":"A structural and primary sequence comparison of the viral RNA-dependent RNA polymerases","volume":"31","author":"Bruenn","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3851\/IMP1729","article-title":"Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir","volume":"21","author":"Buys","year":"2011","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib13","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1007\/s00705-017-3436-8","article-title":"Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication","volume":"162","author":"Cai","year":"2017","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2018.03.003_bib14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1254\/jphs.14156SC","article-title":"Characterization of susceptibility variants of influenza virus grown in the presence of T-705","volume":"126","author":"Daikoku","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.antiviral.2018.03.003_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164691","article-title":"Lethal mutagenesis of hepatitis C virus induced by favipiravir","volume":"11","author":"De \u00c1vila","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.03.003_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.virusres.2017.03.014","article-title":"Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus","volume":"233","author":"de Avila","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib17","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1111\/tbed.12255","article-title":"A refined Guinea pig model of foot-and-mouth disease virus infection for assessing the efficacy of antiviral compounds","volume":"63","author":"De Vleeschauwer","year":"2016","journal-title":"Transbound. Emerg. Dis."},{"key":"10.1016\/j.antiviral.2018.03.003_bib18","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1093\/jac\/dku209","article-title":"Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral","volume":"69","author":"Delang","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib19","series-title":"International Conference on Antiviral Research","article-title":"Can antiviral drug-resistant chikungunya viruses be transmitted by mosquito vectors?","author":"Delang","year":"2017"},{"key":"10.1016\/j.antiviral.2018.03.003_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01400-17","article-title":"Extinction of west nile virus by favipiravir through lethal mutagenesis","volume":"61","author":"Escribano-Romero","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"10.1016\/j.antiviral.2018.03.003_bib22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002614","article-title":"Favipiravir (T-705) inhibits Jun\u00edn virus infection and reduces mortality in a Guinea pig model of Argentine hemorrhagic fever","volume":"7","author":"Gowen","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2018.03.003_bib25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2015.07.003","article-title":"Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever","volume":"121","author":"Gowen","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.01942-16","article-title":"Modeling severe fever with thrombocytopenia syndrome virus infection in golden Syrian hamsters: importance of STAT2 in preventing disease and effective treatment with favipiravir","volume":"91","author":"Gowen","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.03.003_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.antiviral.2017.07.019","article-title":"Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy","volume":"145","author":"Gowen","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib28","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections","volume":"51","author":"Gowen","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib29","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1124\/dmd.111.043828","article-title":"The impact of single nucleotide polymorphisms on human aldehyde oxidase","volume":"40","author":"Hartmann","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.antiviral.2018.03.003_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2017.04.005","article-title":"Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs","volume":"143","author":"Jin","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib31","doi-asserted-by":"crossref","first-page":"e68347","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2019-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.03.003_bib32","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1128\/AAC.01391-15","article-title":"Biochemical evaluation of the inhibition properties of favipiravir and 2\u2019-C-methyl-cytidine triphosphates against human and mouse norovirus RNA polymerases","volume":"59","author":"Jin","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib33","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1128\/AAC.00709-16","article-title":"Antiviral activity of favipiravir (T-705) against a broad range of paramyxoviruses in vitro and against human metapneumovirus in hamsters","volume":"60","author":"Jochmans","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.01074-08","article-title":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106","volume":"53","author":"Julander","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib35","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.antiviral.2009.02.201","article-title":"Effect of T-705 treatment on western equine encephalitis in a mouse model","volume":"82","author":"Julander","year":"2009","journal-title":"Antivir. Res."},{"issue":"72","key":"10.1016\/j.antiviral.2018.03.003_bib36","article-title":"Favipiravir and ribavirin inhibit replication of Asian and African strains of zika virus in different cell models","volume":"10","author":"Kim","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.03.003_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2017.07.010","article-title":"Replication of the Zika virus in different iPSC-derived neuronal cells and implications to assess efficacy of antivirals","volume":"145","author":"Lanko","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01305-16","article-title":"Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses","volume":"61","author":"Madelain","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-015-0364-1","article-title":"Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials","author":"Madelain","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.antiviral.2018.03.003_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004364","article-title":"A rapid screening assay identifies monotherapy with interferon-\u00df and combination therapies with nucleoside analogs as effective inhibitors of Ebola virus","volume":"10","author":"McCarthy","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2018.03.003_bib41","series-title":"Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults","author":"MDVI","year":"2013"},{"key":"10.1016\/j.antiviral.2018.03.003_bib42","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.01219-10","article-title":"T-705 (favipiravir) inhibition of arenavirus replication in cell culture","volume":"55","author":"Mendenhall","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0001342","article-title":"Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever","volume":"5","author":"Mendenhall","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2018.03.003_bib44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","article-title":"Dose regimen of favipiravir for Ebola virus disease","volume":"15","author":"Mentr\u00e9","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.03.003_bib45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.antiviral.2008.07.009","article-title":"Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents","volume":"80","author":"Morrey","year":"2008","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib46","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/mol.113.087247","article-title":"Role of human hypoxanthine Guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)","volume":"84","author":"Naesens","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2018.03.003_bib47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med. Public Health Prep."},{"key":"10.1016\/j.antiviral.2018.03.003_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005389","article-title":"Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted","volume":"11","author":"Nguyen","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2018.03.003_bib49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib50","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of lassa fever","volume":"213","author":"Oestereich","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.03.003_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002804","article-title":"Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever","volume":"8","author":"Oestereich","year":"2014","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2018.03.003_bib52","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01983-17","article-title":"Zika virus (ZIKV) replication is substantially inhibited by novel favipiravir and interferon-alpha combination regimens","author":"Pires de Mello","year":"2017","journal-title":"Antimicrob. Agents Chemother. AAC"},{"key":"10.1016\/j.antiviral.2018.03.003_bib53","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/cid\/cix406","article-title":"Favipiravir and ribavirin treatment of epidemiologically linked cases of lassa fever","volume":"65","author":"Raabe","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.03.003_bib54","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.bbrc.2012.07.034","article-title":"Favipiravir (T-705) inhibits in vitro norovirus replication","volume":"424","author":"Rocha-Pereira","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2018.03.003_bib55","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1128\/AAC.02546-13","article-title":"The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon","volume":"58","author":"Rocha-Pereira","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib56","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/AAC.02198-15","article-title":"Treatment with a nucleoside polymerase inhibitor reduces shedding of murine norovirus in stool to undetectable levels without emergence of drug-resistant variants","volume":"60","author":"Rocha-Pereira","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib57","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/AAC.00886-13","article-title":"Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome","volume":"57","author":"Safronetz","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/srep14775","article-title":"The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset","volume":"5","author":"Safronetz","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2018.03.003_bib59","series-title":"International Control of Foot-and-Mouth Disease: Tools, Trends and Perspectives, 2006. Session of the Research Group of the Standing Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease, 15-21 October, Paphos, Cyprus Ap","first-page":"414","article-title":"The inhibition of FMD virus excretion from the infected pigs by an antiviral agent, T-1105","author":"Sakamoto","year":"2006"},{"key":"10.1016\/j.antiviral.2018.03.003_bib60","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/AAC.00649-13","article-title":"Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase","volume":"57","author":"Sangawa","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib61","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","article-title":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"Scharton","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib62","doi-asserted-by":"crossref","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2018.03.003_bib63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib64","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.1128\/AAC.01375-15","article-title":"Antiviral activity of broad-spectrum and enterovirus-specific inhibitors against clinical isolates of enterovirus D68","volume":"59","author":"Sun","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib65","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.antiviral.2016.06.007","article-title":"Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir","volume":"132","author":"Takashita","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mSphere.00061-15","article-title":"Efficacy of T-705 (favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus","volume":"1","author":"Tani","year":"2016","journal-title":"mSphere"},{"key":"10.1016\/j.antiviral.2018.03.003_bib67","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.antiviral.2017.04.018","article-title":"Antiviral activity of favipiravir (T-705) against mammalian and avian bornaviruses","volume":"143","author":"Tokunaga","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib68","series-title":"International Conference on Antiviral Research","article-title":"Successful design of ribonucleoside Di- and triphosphate prodrugs to improve the anti-influenza virus activity of T-705 and its analogue T-1105","author":"Vanderlinden","year":"2017"},{"key":"10.1016\/j.antiviral.2018.03.003_bib69","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1128\/AAC.01156-16","article-title":"Distinct Effects of T-705 (Favipiravir) and ribavirin on influenza virus replication and viral RNA","volume":"60","author":"Vanderlinden","year":"2016","journal-title":"Synth. Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib70","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1021\/acs.jmedchem.5b01933","article-title":"Synthesis and anti-influenza activity of pyridine, pyridazine, and pyrimidine C-Nucleosides as favipiravir (T-705)","volume":"59","author":"Wang","year":"2016","journal-title":"Analog. J. Med. Chem."},{"key":"10.1016\/j.antiviral.2018.03.003_bib71","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1128\/AAC.01073-16","article-title":"In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71","volume":"60","author":"Wang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.03.003_bib72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2017.10.008","article-title":"Identification of 2\u2032-deoxy-2\u2032-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus","volume":"147","author":"Welch","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib73","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2015.12.006","article-title":"Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses","volume":"126","author":"Westover","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.03.003_bib74","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/infdis\/jiv586","article-title":"Efficacy of favipiravir (T-705) in rabies postexposure prophylaxis","volume":"213","author":"Yamada","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.03.003_bib75","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.bmcl.2017.04.028","article-title":"Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies","volume":"27","author":"Zhang","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2018.03.003_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004695","article-title":"The viral polymerase inhibitor 7-deaza-2\u2019-C-methyladenosine is a potent inhibitor of in vitro zika virus replication and delays disease progression in a robust mouse infection model","author":"Zmurko","year":"2016","journal-title":"PLoS Negl. Trop. Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218300172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218300172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T08:54:46Z","timestamp":1535014486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218300172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":76,"alternative-id":["S0166354218300172"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.03.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}